HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is developing innovative new products to combat the serious threat E. coli O157:H7 contamination poses to the food supply system and to public health. Studies have shown that the Company’s late-stage proprietary product, NXC-4720, is capable of reducing the level of E. coli O157 contamination by over 99%.
